Previous 10 | Next 10 |
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
Lantheus (NASDAQ:LNTH) said on Friday it had begun dosing the first patient in a Phase 2 trial evaluating its imaging agent used to assess PD-L1 expression in cancer cells, NM-01. The trial, dubbed Pelican, is a single-arm trial in non-small cell lung cancer patients. The main ...
NORTH BILLERICA, Mass., May 13, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find...
NORTH BILLERICA, Mass., May 11, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find...
NORTH BILLERICA, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc . (“the Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to...
The strong launch of prostate cancer imaging agent Pylarify will aid in generating nearly double revenues in fiscal 2022, states B. Riley analyst Justin Walsh. Analyst further believes that the Lantheus (LNTH) -11% is well-positioned in the rapidly growing radiopharmaceutical space....
Lantheus Holdings (NASDAQ: LNTH) , which makes diagnostic medical imaging agents that help physicians diagnose and treat cardiovascular and other diseases, saw its shares rise 16.4% on Friday. The stock closed on Thursday at $59.12, then opened on Friday at $68.65, rising to its 52-...
Lantheus Holdings, Inc. (LNTH) Q1 2022 Results Earnings Conference Call April 29, 2022, 08:00 AM ET Company Participants Mark Kinarney - Senior Director, Investor Relations Mary Anne Heino - President and Chief Executive Officer Paul Blanchfield - Chief Commercial Officer Robert Marshall Jr. ...
Gainers: Finch Therapeutics (FNCH) +46%. Zymeworks (ZYME) +44%. Lantheus (LNTH) +13%. BeiGene (BGNE) +12%. Inari Medical (NARI) +11%. Losers: Accolade (ACCD) -55%. Aldeyra Therapeutics (ALDX) -15%. Venus Concept (VERO) -14%. Bio...
Lantheus Holdings (NASDAQ:LNTH), a supplier of diagnostic products, has added ~18% in the pre-market Friday after the company beat Street forecasts with its 1Q 2022 financials and set the 2022 outlook ahead of the consensus. The company's worldwide revenue for the quarter grew ~126% YoY to ~$...
News, Short Squeeze, Breakout and More Instantly...
Lantheus Holdings Inc. Company Name:
LNTH Stock Symbol:
NASDAQ Market:
Lantheus Holdings Inc. Website:
2024-08-01 08:00:12 ET David Turkaly from JMP Securities issued a price target of $125.00 for LNTH on 2024-08-01 07:13:00. The adjusted price target was set to $125.00. At the time of the announcement, LNTH was trading at $104.83. The overall price target consensus is at...
Second Quarter 2024 Worldwide revenue of $394.1 million, an increase of 22.5% from second quarter 2023 Completed three strategic transactions to expand innovative pipeline GAAP fully diluted earnings per share of $0.88, compared to $1.33 in second quarter 2023. Adjusted fully ...
BEDFORD, Mass., July 17, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, July 31, 2024, to discuss its financial and operating results for the second...